Skip to main content

Table 2 Description of therapies used during the study period: trastuzumab patients versus lapatinib patients

From: Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis

 

Trastuzumab

Lapatinib

P-value

 

N = 381

N = 262

 

Number of days between the index date and the end of the study period, mean ± SD

453.3 ± 334.0

412.9 ± 327.1

0.123

Treatment duration (i.e. the number of days between the index date and treatment discontinuation or the end of the study period), mean ± SD

269.1 ± 235.1

179.8 ± 189.0

< 0.001**

Cancer treatments used during the study period, N (%)

   

 Hormonal therapy

110 (28.9)

25 (9.5)

< 0.001**

 Radiation therapy

168 (44.1)

114 (43.5)

0.884

 Surgery (mastectomy)

33 (8.7)

2 (0.8)

< 0.001**

Chemotherapy or anti-angiogenic therapy, N (%)

   

 Any chemotherapy or anti-angiogenic therapya

320 (84.0)

228 (87.0)

0.287

 Capecitabine

71 (18.6)

194 (74.0)

< 0.001**

 Paclitaxel

156 (40.9)

48 (18.3)

< 0.001**

 Docetaxel

112 (29.4)

21 (8.0)

< 0.001**

 Carboplatin

103 (27.0)

25 (9.5)

< 0.001**

 Vinorelbine

86 (22.6)

40 (15.3)

0.022**

 Gemcitabine

51 (13.4)

26 (9.9)

0.184

 Bevacizumab

29 (7.6)

28 (10.7)

0.178

 Doxorubicin

38 (10.0)

21 (8.0)

0.398

 Cyclophosphamide

39 (10.2)

12 (4.6)

0.009**

 Fluorouracil

17 (4.5)

5 (1.9)

0.080

 Ixabepilone

15 (3.9)

15 (5.7)

0.291

 Epirubicin

8 (2.1)

0 (0.0)

-

 Cisplatin

2 (0.5)

3 (1.1)

0.379

 Mitoxantrone

1 (0.3)

1 (0.4)

0.790

 Etoposideb

0 (0.0)

0 (0.0)

-

 Vinblastineb

0 (0.0)

0 (0.0)

-

Any chemotherapy or anti-angiogenic therapy within 28 days following the index date

285 (74.8)

193 (73.7)

0.745

  1. **Denotes statistical significance at the 5% level.
  2. aAny chemotherapy or anti-angiogenic therapy during the study period or at the index date.
  3. bNeither etoposide nor vinblastine were prescribed during the study period.
  4. N, number of patients; SD, standard deviation.